CVS Health (CVS) concluded the recent trading session at $87.6, signifying a -1.4% move from its prior day's close.
CVS raises its 2026 revenue and earnings outlook, but reimbursement pressure, macro headwinds and soft front-store demand could weigh on results.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
CVS Health's Aetna health insurance unit will cut back next year on the preapprovals it requires for treatment for cancer patients to only one medical prior authorization process early on, the company said on Thursday.
Oncology bundling to support all eligible Medicaid members for all cancer types Full roll-out across all Aetna businesses in 2027 HARTFORD, Conn., Sept. 17, 2026 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), is expanding prior authorization bundles across all cancer types for members in eligible1 Medicaid states as of September 1, with plans to expand across all lines of business in 2027.
CVS trades at a forward multiple that screams cheap, yet the street's already bullish and our model runs even hotter. Before you trust either read, there are a few risks that could turn this setup into a trap.
Four winning designs will be featured on limited-edition CVS brand bandages for sale in 2027 WOONSOCKET, R.I., Sept. 16, 2026 /PRNewswire/ -- CVS Health® today announced the launch of its nationwide "Wear Your HeART" Bandage Art Contest, inviting people across the United States to submit original artwork inspired by the importance of protecting personal, family and community health.
CVS Health (CVS) concluded the recent trading session at $94.43, signifying a -1.17% move from its prior day's close.
CVS Health's Health Services arm is gaining from pharmacy strength and improving care delivery, with robust new sales and clinic economics supporting growth.
CVS Health recently posted a revenue jump of 7% year over year. Its shares today seem reasonably valued -- or a bit undervalued.